Report di Analisi - TradeFomo

Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

All AAOI ABUS ABVX ACAD ACRV ADMA AGIO ALMS ALMU ALTS APGE ARTV ASX AUPH AVAV AVPT AXTI BCRX CAI CAKE CEG CELC CEP CGON CIEN CNC COGT CRCL CTMX CTRI DKNG DUOL FLUT GCT GLW GOOG GPCR HALO HCA HIMS HOOD HWM IDYA IREN IVVD KALA KALV KRYS LENZ LEVI LITE LQDA LRMR LULU LUNR MDGL MESO MIRM MOH MPWR MTCH MU MVST NBIS NKE NRIX NUE NVAX NXPI OKUR OLMA ONC ONTO ORKA OSCR PDFS PHAT POET PRLD PYG RBLX RDDT RIGL RKLB SGHC SPRY SRPT TARS TBPH TH TRVI TSHA TTMI UNH VEON VOR WVE XFOR ZBIO ZLAB ZYME

Institutional investors, not retail, drove Prelude's recent stock offering. Major funds like OrbiMed increased their stakes, signaling strong confidence in upcoming clinical catalysts despite the apparent dilution.

The Shadow Accumulation of Prelude Therapeutics: Why The Obvious Dilution is a Trap

2026-04-24BullishStrongChange from report: -17.2%1M: -13.0%3M: -18.5%

Institutional investors, not retail, drove Prelude's recent stock offering. Major funds like OrbiMed increased their stakes, signaling strong confidence in upcoming clinical catalysts despite the apparent dilution.